Last reviewed · How we verify
VIAject®7
At a glance
| Generic name | VIAject®7 |
|---|---|
| Sponsor | Biodel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of Ketone Bodies on Insulin Sensitivity (NA)
- Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. (PHASE3)
- The Accuracy of Continuous Glucose Monitoring Systems in Critically Ill Patients
- Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (NA)
- Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® (NA)
- Propranolol for Sleep Apnea Therapy (PHASE2)
- Empagliflozin Effect on Glucose Toxicity (PHASE4)
- A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIAject®7 CI brief — competitive landscape report
- VIAject®7 updates RSS · CI watch RSS
- Biodel portfolio CI